BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
OCREVUS ZUNOVO (ocrelizumab and hyaluronidase) by Roche is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2024.
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCREVUS ZUNOVO is a CD20-directed monoclonal antibody combined with hyaluronidase for subcutaneous injection, approved September 2024. It works by targeting CD20-positive B cells to modulate immune response. The hyaluronidase component enables rapid subcutaneous delivery, improving patient convenience over intravenous administration.
Growth
Recent approval positions this as a growth-stage asset with expanding market opportunity; commercial teams are in early-stage demand generation and market development phase.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Ocrevus Zunovo for MS: Mixed Methods
Started Jun 2026
150 enrolled
Multiple Sclerosis
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
Started Nov 2018
51 enrolled
Multiple SclerosisRelapsePrimary Progressive Multiple Sclerosis
Career Relevance
OCREVUS ZUNOVO offers career opportunity in a newly approved, growth-stage biologic from a large pharmaceutical sponsor with deep infrastructure. Roles span commercial launch strategy, patient access solutions, medical education, and ongoing regulatory management of a novel delivery innovation.
Worked on OCREVUS ZUNOVO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.